title: [Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
abstract: Research groups were formed in 20 institutions nationwide to investigate carbapenem resistance of clinical isolates. Activities of various antibacterial agents, principally carbapenems, were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of 17 antibacterial agents for 1,326 strains of 11 bacterial species isolated at the institutions between October and December 1994. The results are as follows: 1. Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae. Their activities against Enterococcus faecalis were comparable to that of ABPC. Carbapenems showed low activities against MRSA. 2. OFLX exhibited the greatest antibacterial activity against Haemophilus influenzae, followed by MEPM. Antibacterial activities of the other carbapenems were comparable to those of FMOX, CTM, and ABPC. 3. The carbapenems showed high activities against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Bacteroides fragilis group. Their activities were greater than those exhibited by other beta-lactam antibacterial agents. The carbapenems also exhibited stronger antibacterial activities against Serratia marcescens than the other beta-lactam antibacterial agents, but some resistant strains were detected. 4. The antibacterial activities of carbapenems against Pseudomonas aeruginosa were comparable to those of CAZ, AZT, AMK.
authors.affiliation: Department of Clinical Pathology, Juntendo University, School of Medicine.
authors.forename: J
authors.initials: J
authors.lastname: Igari
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Nishino
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Uehara
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Imafuku
authors.forename: T
authors.initials: T
authors.lastname: Shibano
authors.forename: S
authors.initials: S
authors.lastname: Satou
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Yomoda
authors.forename: T
authors.initials: T
authors.lastname: Oguri
authors.forename: K
authors.initials: K
authors.lastname: Kumasaka
authors.forename: J
authors.initials: J
authors.lastname: Okada
authors.forename: Y
authors.initials: Y
authors.lastname: Hirata
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.forename: R
authors.initials: R
authors.lastname: Kawaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Ohtaki
authors.forename: S
authors.initials: S
authors.lastname: Ishigo
authors.forename: E
authors.initials: E
authors.lastname: Okamoto
authors.forename: E
authors.initials: E
authors.lastname: Murakami
authors.forename: K
authors.initials: K
authors.lastname: Matsuoka
authors.forename: K
authors.initials: K
authors.lastname: Tokuda
authors.forename: H
authors.initials: H
authors.lastname: Saeki
mesh_terms: D042462:4-Quinolones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D015780:Carbapenems / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006095:Gram-Positive Cocci / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D000077731:Meropenem; D008997:Monobactams / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012706:Serratia marcescens / Q000187:drug effects; D013845:Thienamycins / Q000494:pharmacology*
chemical_list: D042462:4-Quinolones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D015780:Carbapenems; D002511:Cephalosporins; D008997:Monobactams; D010406:Penicillins; D013845:Thienamycins; D015378:Imipenem; D000077731:Meropenem; C039536:panipenem; C065257:biapenem